[SCHEDULE 13D] CG Oncology, Inc. SEC Filing

Rhea-AI Filing Summary

Longitude-affiliated investors disclosed ownership in CG Oncology (CGON), holding a combined economic interest of 4,662,268 shares, representing 6.0% of the outstanding common stock based on 77,762,732 shares. Record owners include Longitude Venture Partners IV, L.P. (3,190,463 shares, 4.1%) and Longitude Prime Fund, L.P. (1,471,805 shares, 1.9%). The filing describes prior private purchases of preferred and common stock between 2022 and 2023 that converted into common stock upon the issuer’s IPO. The Reporting Persons say holdings are for general investment purposes, reserve the right to change their position, and note that a Longitude managing director serves on CG Oncology’s board. The filing references investor registration rights and disclaims current plans for any specific corporate actions.

Positive

• Established ownership position: Reporting Persons collectively beneficially own 4,662,268 shares (6.0%) of CG Oncology common stock.
• Clear transaction history: Purchases from 2022–2023 and IPO conversion are documented, providing transparency on source of holdings.
• Board access: A Longitude managing director serves on the issuer’s board, enabling direct engagement with management.
• Registration rights: Reporting Persons are party to an Amended and Restated Investors' Rights Agreement, providing potential liquidity options.

Negative

• Group ambiguity: The filing disclaims group status yet references policies and Seven Fleet ownership that may create interpretive ambiguity about coordination.
• No specified plans: The Reporting Persons state only general investment intent and reserve the right to change strategy, leaving uncertainty about future actions.
• Concentration but not control: The stake is material but below typical control thresholds, limiting immediate ability to effect major corporate changes.

Insights

Financial Analyst

TL;DR: Longitude entities hold a modest but visible 6.0% stake in CGON acquired through prior private rounds and post-IPO conversion.

The filing details the provenance of the stake: multiple preferred and secondary purchases in 2022–2023 that converted at IPO into common shares. The position size is material enough to merit investor attention but is below levels typically associated with control. The Reporting Persons emphasize general investment intent and reserve flexibility to trade, which implies no immediate activist agenda. The presence of a Longitude managing director on the board increases their ability to influence governance through engagement rather than overt control.

Corporate Governance Expert

TL;DR: The Schedule 13D discloses concentrated ownership and board access but includes disclaimers about group status and no present plans to effect structural change.

Material governance elements include registration rights under an Investors' Rights Agreement and a board seat held by a Longitude representative, enabling ongoing dialogue with management. The Reporting Persons expressly disclaim being a group yet acknowledge policies that could be interpreted otherwise concerning Seven Fleet. This mixed disclosure is legally cautious and signals monitoring and potential future engagement while avoiding commitments to specific proposals or transactions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

CG Oncology, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

156944100

(CUSIP Number)

Patrick G. Enright
Longitude Capital Partners IV, LLC, 2740 Sand Hill Road, 2nd Floor
Menlo Park, CA, 94025
(650) 854-5700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/11/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 156944100

1

Name of reporting person

Longitude Capital Partners IV, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,190,463.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,190,463.00

11

Aggregate amount beneficially owned by each reporting person

3,190,463.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

All such shares are held of record by LVPIV (as defined in Item 2(a) below). LCPIV (as defined in Item 2(a) below) is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock (as defined in Item 2(d) below) outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer (as defined in Item 1(b) below) in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission (the "Commission") on August 8, 2025 (the "Form 10-Q"), plus (ii) 1,515,151 Shares purchased by Seven Fleet (as defined in Item 5(a) below) on September 11, 2025.

SCHEDULE 13D

CUSIP No. 156944100

1

Name of reporting person

Longitude Venture Partners IV, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,190,463.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,190,463.00

11

Aggregate amount beneficially owned by each reporting person

3,190,463.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All such shares are held of record by LVPIV. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.

SCHEDULE 13D

CUSIP No. 156944100

1

Name of reporting person

Longitude Prime Partners, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,471,805.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,471,805.00

11

Aggregate amount beneficially owned by each reporting person

1,471,805.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

All such shares are held of record by LPF (as defined in Item 2(a) below). LPP (as defined in Item 2(a) below) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.

SCHEDULE 13D

CUSIP No. 156944100

1

Name of reporting person

Longitude Prime Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,471,805.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,471,805.00

11

Aggregate amount beneficially owned by each reporting person

1,471,805.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All such shares are held of record by LPF. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.

SCHEDULE 13D

CUSIP No. 156944100

1

Name of reporting person

Patrick G. Enright

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,662,268.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,662,268.00

11

Aggregate amount beneficially owned by each reporting person

4,662,268.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

All such shares are held of record by LVPIV and LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to the shares held by LVPIV. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Mr. Enright is a managing member of each of LCPIV and LPP and may be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.

SCHEDULE 13D

CUSIP No. 156944100

1

Name of reporting person

Juliet Tammenoms Bakker

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,662,268.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,662,268.00

11

Aggregate amount beneficially owned by each reporting person

4,662,268.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

All such shares are held of record by LVPIV and LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to the shares held by LVPIV. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Ms. Bakker is a managing member of each of LCPIV and LPP and may be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: CG Oncology, Inc.
(c)	Address of Issuer's Principal Executive Offices: 400 Spectrum Center Drive, Suite 2040, Irvine, CALIFORNIA , 92618.
Item 2.	Identity and Background
(a)	This joint statement on Schedule 13D is being filed by Longitude Capital Partners IV, LLC ("LCPIV"), Longitude Venture Partners IV, L.P. ("LVPIV"), Longitude Prime Partners, LLC ("LPP") and Longitude Prime Fund, L.P. ("LPF", and together with LCPIV, LVPIV and LPP, the "Reporting Entities") and Patrick G. Enright and Juliet Tammenoms Bakker (together, the "Reporting Individuals"). The Reporting Entities and the Reporting Individuals are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The securities were previously reported on a Schedule 13G filed with the Commission on February 5, 2024 (the "Schedule 13G"). The Schedule 13G was filed pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Exchange Act is attached to this Schedule 13D as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Schedule 13D except to the extent of such Reporting Person's pecuniary interest therein.
(b)	The address of the principal business office of each Reporting Person is 2740 Sand Hill Road, 2nd Floor, Menlo Park, CA 94025.
(c)	Each Reporting Entity is a venture capital investment entity. Each Reporting Individual is engaged through venture capital investment entities in acquiring, holding and disposing of interests in various companies for investment purposes. The Reporting Individuals are managing members of LCPIV and LPP. LCPIV is the general partner of LVPIV. LPP is the general partner of LPF
(d)	During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	LCPIV and LPP are limited liability companies organized under the laws of the State of Delaware. LVPIV and LPF are limited partnerships organized under the laws of the State of Delaware. Each of the Reporting Individuals is a citizen of the United States of America.
Item 3.	Source and Amount of Funds or Other Consideration
	In September 2022, LVPIV purchased 21,547,685 shares of the Issuer's Series E redeemable convertible preferred stock for a purchase price of $1.0674 per share and an aggregate purchase price of $22,999,998.97. In May 2023, LVPIV entered into a common stock transfer agreement with various holders of the Issuer's capital stock pursuant to which LVPIV purchased 8,873,500 shares of common stock at a purchase price of $0.80055 per share for an aggregate purchase price of $7,103,680.43 (the "May 2023 Longitude Secondary Transaction"). In connection with the May 2023 Longitude Secondary Transaction, the Issuer entered into a common stock transfer agreement with LVPIV and each seller pursuant to which, among other things, the Issuer waived its right of first refusal to purchase the shares of common stock sold in the May 2023 Longitude Secondary Transaction. In July 2023, LPF purchased 4,402,320 shares of the Issuer's Series F redeemable convertible preferred stock for a purchase price of $1.2872 per share and an aggregate purchase price of approximately $5.6 million. In July 2023, LPF entered into a stock transfer agreement with Lepu Holdings Limited pursuant to which LPF purchased 3,512,646 shares of Series C redeemable convertible preferred stock from Lepu Holdings Limited at a purchase price of $0.9073 per share for an aggregate purchase price of $3,187,023.72 (the "July 2023 Longitude Secondary Transaction"). Jue Pu, a former director of the Issuer, was an affiliate of Lepu Holdings Limited at the time of the July 2023 Longitude Secondary Transaction. In August 2023, LPF entered into a stock transfer agreement with an entity affiliated with a holder of the Issuer's capital stock pursuant to which LPF sold 1,756,323 shares of Series C redeemable convertible preferred stock at a sale price of $0.9073 per share for an aggregate sale price of $1,593,511.86 (the "August 2023 Longitude Secondary Transaction"). In connection with the August 2023 Longitude Secondary Transaction and the July 2023 Longitude Secondary Transaction, the Issuer entered into stock transfer agreements with LPF and each counterparty. In October 2023, Abundant Supply Global Limited, an entity affiliated with ORI Capital, a greater than 5% stockholder the Issuer, entered into stock transfer agreements with certain other holders of the Issuer's capital stock pursuant to which Abundant Supply Global Limited sold an aggregate of 27,190,800 shares of Series C redeemable convertible preferred stock at a purchase price of $1.2872 per share for an aggregate purchase price of $34,999,997.84. In connection with these transactions, LPF purchased 3,107,520 shares of Series C redeemable convertible preferred stock from Abundant Supply Global Limited for an aggregate purchase price of approximately $4 million. On January 29, 2024, effective upon the closing of the Issuer's initial public offering of its Common Stock (the "Offering"), each series of the Issuer's preferred stock automatically converted into shares of the Issuer's Common Stock on a one-for-9.535 basis for no consideration. All shares of the capital stock of the Issuer purchased by LVPIV and LPF have been purchased using investment funds provided to LVPIV and LPF by its limited partner and general partner investors. Unless noted above, no part of the purchase price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.
Item 4.	Purpose of Transaction
	The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. In addition, Brian Liu, a managing director at LCM, serves on the board of directors of the Issuer. In such capacity, Mr. Liu, as well as other representatives of LCM or the Reporting Entities, expect to engage in communications from time to time with one or more shareholders, officers or members of the Issuer, including discussions regarding the Issuer's operations and strategic direction and ideas that, if effected, could result in, among other things, any of the matters identified in Item 4(a)-(j) of Schedule 13D. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve their right, based on all relevant factors and subject to applicable law, at any time or from time to time, to review or reconsider their position, change their purpose, take other actions (including actions that could involve one or more of the types of transactions or have one or more of the results described in Items 4(a)-(j) of Schedule 13D) or formulate and implements plans or proposals with respect to any of the foregoing.
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-11 of the cover pages of this Statement and Item 2(a) above. LVPIV is the record owner of 3,190,463 shares of Common Stock (the LVPIV Shares) and LPF is the record owner of 1,471,805 shares of Common Stock (the LPF Shares). As general partner of LVPIV, LCPIV may be deemed to beneficially own the LVPIV Shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may be deemed to share voting, investment and dispositive power with respect to the LVPIV Shares. As general partner of LPF, LPP may be deemed to beneficially own the LPF Shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power with respect to the LPF Shares. * Except to the extent of his, hers, or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. Longitude Capital Management Co. LLC ("LCM"), the investment advisor of LVPIV and LPF, and Seven Fleet Advisors LLC (together with its affiliates, "Seven Fleet") have instituted policies and procedures that may affect the acquisition, holding and disposition of securities held by Seven Fleet. As a result of such policies and procedures, the Reporting Persons and Seven Fleet may be deemed to be members of a group within the meaning of Section 13(d)(3) of the Exchange Act. As of the date hereof, based on information provided by or on behalf of Seven Fleet, Seven Fleet may be deemed to be the beneficial owner of 1,515,151 shares of Common Stock, constituting 1.9% of the number of shares of Common Stock outstanding (based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet September 11, 2025). Notwithstanding such policies and procedures, the Reporting Persons expressly disclaim such group membership and beneficial ownership over any Common Stock that they may be deemed to beneficially own by reason of such policies and procedures. This Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 of the Exchange Act or for any other purpose.
(b)	See Items 7-11 of the cover pages of this Statement and Item 2(a) and Item 5(a) above.
(c)	Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.
(d)	Under certain circumstances set forth in the limited partnership agreements of LVPIV and LPF, the general partner and limited partners of LVPIV and LPF, respectively, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.
(e)	Not applicable
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Persons and certain of the Issuer's other investors entered into the Amended and Restated Investors' Rights Agreement, dated July 28, 2023 (the "Rights Agreement"). After the closing of the Offering, the stockholders party thereto are entitled to certain registration rights, including the right to demand that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1 (File No. 333-276350) and declared effective by the Commission on January 24, 2024 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1: Joint Filing Agreement, dated September 18, 2025, by and among the Reporting Persons (filed herewith). Exhibit 2: Amended and Restated Investors' Rights Agreement, dated July 28, 2023, by and among the Registrant and certain of its stockholders, (filed as Exhibit 4.2 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 23, 2024 (SEC File No. 333-276350) and incorporated herein by reference).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Longitude Capital Partners IV, LLC

Signature:	/s/ Cristiana Blauth Oliveira
Name/Title:	Cristiana Blauth Oliveira, Authorized Signatory
Date:	09/18/2025

Longitude Venture Partners IV, L.P.

Signature:	/s/ Cristiana Blauth Oliveira
Name/Title:	Cristiana Blauth Oliveira, Authorized Signatory
Date:	09/18/2025

Longitude Prime Partners, LLC

Signature:	/s/ Cristiana Blauth Oliveira
Name/Title:	Cristiana Blauth Oliveira, Authorized Signatory
Date:	09/18/2025

Longitude Prime Fund, L.P.

Signature:	/s/ Cristiana Blauth Oliveira
Name/Title:	Cristiana Blauth Oliveira, Authorized Signatory
Date:	09/18/2025

Patrick G. Enright

Signature:	/s/ Cristiana Blauth Oliveira
Name/Title:	Cristiana Blauth Oliveira as attorney-in-fact for Patrick G. Enright
Date:	09/18/2025

Juliet Tammenoms Bakker

Signature:	/s/ Cristiana Blauth Oliveira
Name/Title:	Cristiana Blauth Oliveira as attorney-in-fact for Juliet Tammenoms Bakker
Date:	09/18/2025

FAQ

How many CG Oncology (CGON) shares do Longitude-related entities beneficially own?

The Reporting Persons beneficially own 4,662,268 shares, representing 6.0% of CGON's outstanding common stock based on 77,762,732 shares.

Which Longitude entities hold CGON shares and what are their record amounts?

Longitude Venture Partners IV, L.P. holds 3,190,463 shares (4.1%); Longitude Prime Fund, L.P. holds 1,471,805 shares (1.9%).

Were the shares acquired in private transactions prior to CG Oncology’s IPO?

Yes. The filing details preferred and secondary purchases in 2022–2023 that converted into common stock upon the issuer’s IPO.

Do the Reporting Persons intend to take control or propose major corporate actions at CGON?

No specific plans are disclosed. The Reporting Persons state their holdings are for general investment purposes and reserve the right to change their position.

Does Longitude have board representation at CG Oncology?

Yes. The filing states that Brian Liu, a managing director at Longitude Capital Management Co., serves on CG Oncology’s board of directors.